Pediatrix Medical Group (NYSE:MD – Get Free Report) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Wednesday.
Other analysts have also issued reports about the company. UBS Group lifted their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Macquarie began coverage on shares of Pediatrix Medical Group in a research report on Monday, December 16th. They set an “outperform” rating and a $18.00 target price on the stock. Truist Financial reduced their target price on shares of Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating on the stock in a report on Monday, January 6th. Mizuho raised their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $16.25.
Check Out Our Latest Stock Analysis on Pediatrix Medical Group
Pediatrix Medical Group Stock Up 0.6 %
Pediatrix Medical Group (NYSE:MD – Get Free Report) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. During the same period in the prior year, the company earned $0.29 EPS. The firm’s quarterly revenue was up .9% compared to the same quarter last year. As a group, equities research analysts anticipate that Pediatrix Medical Group will post 1.26 EPS for the current fiscal year.
Insiders Place Their Bets
In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of Pediatrix Medical Group stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company’s stock.
Institutional Investors Weigh In On Pediatrix Medical Group
A number of hedge funds have recently made changes to their positions in the business. Quest Partners LLC lifted its stake in Pediatrix Medical Group by 25.6% in the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after purchasing an additional 622 shares during the last quarter. Quarry LP lifted its position in shares of Pediatrix Medical Group by 54.1% during the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after buying an additional 1,662 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Pediatrix Medical Group during the 2nd quarter worth $72,000. CWM LLC grew its stake in shares of Pediatrix Medical Group by 134.0% during the 3rd quarter. CWM LLC now owns 6,427 shares of the company’s stock worth $74,000 after acquiring an additional 3,681 shares during the period. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in Pediatrix Medical Group in the 2nd quarter worth about $81,000. 97.71% of the stock is currently owned by institutional investors.
About Pediatrix Medical Group
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Read More
- Five stocks we like better than Pediatrix Medical Group
- There Are Different Types of Stock To Invest In
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- How to Invest in Blue Chip Stocks
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Upcoming IPO Stock Lockup Period, Explained
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.